Oppenheimer analyst Francois Brisebois lowered the firm’s price target on Compass Pathways to $33 from $55 and keeps an Outperform rating on the shares, citing difficult market conditions. Compass presented new data from an open-label Investigator-Initiated Trial of 25mg COMP360 for Bipolar type II depression and post-hoc analysis from the successful Phase 2b in TRD at ACNP, and Brisebois believes early positive signals, including a substantial reduction in depressive symptoms in 12/14 participants from baseline, is promising, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CMPS:
- Here’s What You Missed in Cannabis This Week
- Compass Pathways presents new COMP360 psilocybin therapy data
- COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
- Analysts Say These 2 Stocks Could Double Your Money — Here’s Why They Could Jump
- Rising High: Exclusive talk with psychedelic biopharma firm Cybin